IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v136y2023ics016885102300177x.html
   My bibliography  Save this article

Value assessment of antimicrobials using the STEDI framework – How steady is the outcome?

Author

Listed:
  • Brassel, Simon
  • Al Taie, Amer
  • Steuten, Lotte

Abstract

Antimicrobial resistance (AMR) is one of the major threats to global population health, and the antimicrobial market requires substantial reimbursement reform and/or significant financial incentives to function properly.

Suggested Citation

  • Brassel, Simon & Al Taie, Amer & Steuten, Lotte, 2023. "Value assessment of antimicrobials using the STEDI framework – How steady is the outcome?," Health Policy, Elsevier, vol. 136(C).
    • Handle: RePEc:eee:hepoli:v:136:y:2023:i:c:s016885102300177x
    DOI: 10.1016/j.healthpol.2023.104892
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S016885102300177X
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2023.104892?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Adrian Towse & Rachel Silverman Bonnifield, 2022. "An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment," Policy Papers 277, Center for Global Development.
    2. Benjamin Plackett, 2020. "Why big pharma has abandoned antibiotics," Nature, Nature, vol. 586(7830), pages 50-52, October.
    3. Eleanor Bell & Margherita Neri & Lotte Steuten, 2022. "Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 105-117, January.
    4. Karlsberg Schaffer, S. & West, P. & Towse, A. & Henshall, C. & Mestre-Ferrandiz, J. & Masterson, R. & Fischer, A., 2017. "Additional Elements of Value for Health Technology Assessment Decisions," Briefings 001851, Office of Health Economics.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.
    2. Margherita Neri;Adrian Towse, 2017. "Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?," Briefing 001922, Office of Health Economics.
    3. Xinghong Zhao & Xinyi Zhong & Shinong Yang & Jiarong Deng & Kai Deng & Zhengqun Huang & Yuanfeng Li & Zhongqiong Yin & Yong Liu & Jakob H. Viel & Hongping Wan, 2024. "Guiding antibiotics towards their target using bacteriophage proteins," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    4. Colm Leonard & Nick Crabb & David Glover & Sophie Cooper & Jacoline Bouvy & Milena Wobbe & Mark Perkins, 2023. "Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?," Applied Health Economics and Health Policy, Springer, vol. 21(3), pages 365-372, May.
    5. Heyen, Nils B. & Zenker, Andrea & Aichinger, Heike & Bratan, Tanja & Kaufmann, Tanja & Schnabl, Esther, 2024. "Innovation without growth? Exploring the (in)dependency of innovation on economic growth," Discussion Papers "Innovation Systems and Policy Analysis" 83, Fraunhofer Institute for Systems and Innovation Research (ISI).
    6. Belma Skender, 2024. "The demise of the antibiotic pipeline: the Bayer case," Palgrave Communications, Palgrave Macmillan, vol. 11(1), pages 1-10, December.
    7. Jason Gordon & Oliver Darlington & Phil McEwan & Matthew Lumley & Amer Taie & Meagen Hicks & Claudie Charbonneau & Angela Blake & Neil Hawkins & Simon Goldenberg & Jonathan Otter & Mark Wilcox, 2020. "Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model," PharmacoEconomics, Springer, vol. 38(8), pages 857-869, August.
    8. Sofie Larsson & Charlotta Edlund & Pontus Nauclér & Mikael Svensson & Anders Ternhag, 2022. "Cost-Effectiveness Analysis of Temocillin Treatment in Patients with Febrile UTI Accounting for the Emergence of Antibiotic Resistance," Applied Health Economics and Health Policy, Springer, vol. 20(6), pages 835-843, November.
    9. Nadya Wells & Vinh-Kim Nguyen & Stephan Harbarth, 2024. "Novel insights from financial analysis of the failure to commercialise plazomicin: Implications for the antibiotic investment ecosystem," Palgrave Communications, Palgrave Macmillan, vol. 11(1), pages 1-13, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:136:y:2023:i:c:s016885102300177x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.